Table 2.

Rate of early ADAMTS13 recovery and relapse

No. of episodesMean ADAMTS13 recovery slope95% CIP
Treatment    .11 
 Rituximab 103 0.9 0.82-0.99  
 Corticosteroids alone 13 0.96 0.73-1.19  
 Other 12 0.65 0.39-0.90  
Race    .89 
 Black 79 0.88 0.79-0.98  
 White 43 0.91 0.76-1.06  
 Other/unknown 6 0.96 0.61-1.32  
 No. of episodes HR (per +0.25 increase in ADAMTS13 recovery slope) 95% CI P 
All 128 0.79 0.64-0.98 .03 
Rituximab only 103 0.92 0.71-1.18 .5 
De novo, rituximab 28 0.58 0.18-1.83 .35 
Relapsed, rituximab 75 0.99 0.75-1.31 .94 
No. of episodesMean ADAMTS13 recovery slope95% CIP
Treatment    .11 
 Rituximab 103 0.9 0.82-0.99  
 Corticosteroids alone 13 0.96 0.73-1.19  
 Other 12 0.65 0.39-0.90  
Race    .89 
 Black 79 0.88 0.79-0.98  
 White 43 0.91 0.76-1.06  
 Other/unknown 6 0.96 0.61-1.32  
 No. of episodes HR (per +0.25 increase in ADAMTS13 recovery slope) 95% CI P 
All 128 0.79 0.64-0.98 .03 
Rituximab only 103 0.92 0.71-1.18 .5 
De novo, rituximab 28 0.58 0.18-1.83 .35 
Relapsed, rituximab 75 0.99 0.75-1.31 .94 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal